A de-risked small molecule with multi-indication upside- starting with CADASIL.
X1 Biotech is advancing X101 (Ro24-7429), a repurposed small-molecule RUNX1 inhibitor, through a capital-efficient CADASIL-first pathway with expansion potential across serious vascular-degeneration and fibrotic diseases, including IPF.
At a glance
Asset: X101 (Ro24-7429) - repurposed small molecule
Strategy: CADASIL-first (orphan beachhead) → expansion into larger indications (e.g., IPF)
De-risking: prior human exposure from historical clinical development + preclinical efficacy in relevant models
Regulatory: successful FDA PRE‑IND interaction supporting the IPF plan
IP: options on issued patents + additional filings in process
Why this matters
High unmet need: CADASIL is a deadly disease with no FDA‑approved pharmaceutical therapy
Efficient development path: orphan-first approach designed for faster clinical learning and clearer value inflection
One mechanism, multiple shots on goal: potential relevance across vascular degeneration and fibrotic diseases
Small-molecule economics: scalable manufacturing profile to support broad commercialization
Progress to date
Identified X101 as a therapeutic that can modulate proteins regulating blood vessel development and repair
Demonstrated preclinical efficacy in animal models relevant to target diseases (including pulmonary fibrosis and CADASIL models)
Secured broad IP position (issued patents under option + additional filings in process)
Completed a successful FDA PRE‑IND interaction supporting the pulmonary fibrosis development plan
Defined a CADASIL-first clinical strategy to reduce time and cost to clinical proof
What we’re building toward
A focused, milestone-driven development plan designed to generate clinical proof in CADASIL and progress into larger indications -positioning X1 Biotech for strategic partnership or acquisition as value is created.
Request the Investor Overview
For data, IP position, development roadmap, and financing needs.